Clinical Trials Browser

Phase 1/2 × Appendiceal Neoplasms × 90 days × Clear all

NCT05194995 2026-03-16

JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation

Phase 1/2 Active not recruiting

Gastrointestinal

Appendiceal Neoplasms